InvestorsHub Logo
Followers 80
Posts 1038
Boards Moderated 0
Alias Born 06/26/2014

Re: None

Wednesday, 06/08/2016 6:44:45 AM

Wednesday, June 08, 2016 6:44:45 AM

Post# of 426436
FORM 8K AMARIN

On June 7, 2016, Watson Laboratories filed a motion for voluntary dismissal requesting the court to terminate its own appeal of Jan 22, 2016.......The motion by Watson, to which Amarin has consented, follows the May 31, 2016 FDA grant of 5 Year, NCE with respect to Vascepa.
Once the court of Appeals grants Watson's unopposed motion to dismiss the appeal, there will be no pending patent litigation related to Vascepa
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News